ASH winners and losers: Hemophilia therapies show promise, Syros stumbles

A

TLANTA — This weekend’s American Society of Hematology (ASH) annual meeting was bit like playing in a Brooklyn children’s soccer tournament: Everyone got a congratulatory trophy just for showing up.

Well … not everyone. To extend the tortured P.C. soccer metaphor, Syros Pharmaceuticals (SYRS) was ejected with a red card. Unsportsmanlike conduct.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

What is STAT Plus?

About the Author

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street.

adam.feuerstein@statnews.com

@adamfeuerstein

Tags

cancer

drug development

pharmaceuticals

rare disease